Tharimmune to Present at the Microcap Conference 2025
-
Top Russian official in Washington for talks on improving ties
-
Sinner's former physio to blame for failed dope tests, says ex-physical trainer
-
Germany slams Trump tariffs, US tech titans in crosshairs
-
Trump tariff blitz sparks retaliation threats, economic fears
-
Search for Malaysia's long missing MH370 suspended
-
Hungary announces ICC withdrawal as Israel's Netanyahu visits
-
Trump's tariffs sting Asian giants, including US allies
-
India says 'examining the implications' of US tariffs
-
Evenepoel set to make injury return at Tour de Romandie
-
USA sole bidder for 2031 Women's World Cup, UK set to host in 2035 - Infantino
-
McLaren's Norris says it's 'our turn' for success
-
Lessons and liquids: buried alive in Myanmar's earthquake
-
Trump tariffs spark fears for Asian jobs, exporting sectors
-
Stocks and dollar sink, havens rally as Trump tariffs fan trade war
-
Runners fly to North Korea for first post-Covid Pyongyang Marathon
-
Hamilton rubbishes claims he's lost faith in Ferrari
-
Nintendo Switch 2 sparks excitement despite high price
-
Sri Lanka's crackdown on dogs for India PM's visit sparks protest
-
S Korea police raise security levels ahead of impeachment verdict
-
China vows 'countermeasures' to sweeping new US tariffs
-
Trump jolts allies, foes and markets with tariff blitz
-
France says EU to target US online services after Trump tariffs
-
Tsunoda vows to bring 'something different' after Red Bull promotion
-
Verstappen not happy with Tsunoda-Lawson Red Bull swap
-
Experts accuse 54 top Nicaragua officials of grave abuses
-
Remains of 30th victim of Los Angeles fires found
-
EU to target US online services after Trump tariffs: France
-
How Trump's 'liberation day' tariffs will impact China
-
Malaysia suspends search for long-missing flight MH370
-
Search for long-missing flight MH370 suspended: Malaysia minister
-
Europe hits out at Trump tariffs, keeps door open for talks
-
Myanmar's junta chief to head to Bangkok summit as quake toll surpasses 3,000
-
Lawson vows to prove he belongs in F1 after shock of Red Bull axing
-
Australia sweats through hottest 12 months on record: official data
-
Livestock theft is central to jihadist economy in west Africa
-
South African artist champions hyenas in 'eco-queer' quest
-
Danish PM in 'unity' Greenland visit amid US takeover threats
-
Taiwan says US tariffs 'highly unreasonable'
-
Lawson says ruthless Red Bull axing was 'tough to hear'
-
Heat humble Celtics for sixth straight win, Thunder roll on
-
Trump escalates trade war with sweeping global tariffs
-
Japan says US tariffs 'extremely regrettable', may break WTO rules
-
South Koreans anxious, angry as court to rule on impeached president
-
Juve at in-form Roma with Champions League in the balance
-
Injuries put undermanned Bayern's title bid to the test
-
Ovechkin scores 892nd goal -- three away from Gretzky's NHL record
-
Australian former rugby star Petaia signs for NFL's Chargers
-
China says opposes new US tariffs, vows 'countermeasures'
-
Athletics world watching as 'Grand Slam Track' prepares for launch
-
Heat humble Celtics for sixth straight win, Cavs top Knicks
Tharimmune to Present at the Microcap Conference 2025
BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.
Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.
Event: The Microcap Conference 2025
Location: Studio 4, Borgata Hotel Casino & Spa
Date: Thursday January 30, 2025
Time: 10:00 AM Eastern Time
Investors interested in meeting with management can register for the conference here.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.
Contacts
Tharimmune, Inc.
[email protected]
Alliance Advisors IR
Tirth T. Patel
[email protected]
212-201-6614
Contact Information
Tirth Patel
Alliance Advisors IR
[email protected]
1-212-201-6614
SOURCE: Tharimmune Inc.
View the original press release on ACCESS Newswire
M.A.Colin--AMWN
